Completion of Aspen Global's acquisition of Australian product portfolio from GSK ASPEN PHARMACARE HOLDINGS LIMITED (Incorporated in the Republic of South Africa) Registration number: 1985/0002935/06 Share code: APN ISIN: ZAE000066692 (“Aspen Holdings”) COMPLETION OF ASPEN GLOBAL’S ACQUISITION OF AUSTRALIAN PRODUCT PORTFOLIO FROM GSK Shareholders are referred to the Aspen Holdings SENS announcement of 15 August 2012 in which shareholders were advised that Aspen Global Incorporated (“Aspen Global”), a wholly owned subsidiary of Aspen Holdings, had reached agreement with GlaxoSmithKline plc (“GSK”) for the acquisition of a portfolio of 25 established pharmaceutical products (“the Products”) distributed in Australia (“the Transaction”). The Transaction was subject to the following conditions precedent: -The approval of the Australian competition authorities; and -The approval of the Australian Foreign Investment Review Board. Aspen Holdings is pleased to announce that both these conditions precedent have been met and that the Transaction has, as a result, been completed with effect from 30 November 2012. Shareholders are further advised that the final consideration in respect of the Transaction has reduced from GBP 172.0 million to GBP 163.8 million. This reduction was due to the completion of the Transaction being subject to one of the pharmaceutical products originally included in the Transaction being excluded and the completion of the Transaction being delayed beyond 31 October 2012. Durban 3 December 2012 Sponsor: Investec Bank Limited Date: 03/12/2012 08:00:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on, information disseminated through SENS.